Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Among other segments, the company’s biologic products such as DBMs and synthetic bone grafts have application in general orthopaedic, spine and sports-medicine procedures.
The company raised $7.4MM in its last round of funding, in 2013.
Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Among other segments, the company's biologic products such as DBMs and synthetic bone grafts have application in general orthopaedic, spine and sports-medicine procedures.
Vivex Biomedical raised US $6.6MM of a potential $10MM offering of Series A Convertible Preferred Stock. Among other segments, the company’s biologic products such as DBMs and synthetic bone grafts have application in general orthopaedic, spine and sports-medicine procedures.
Copy to clipboard 
